MTOR and ovarian carcinoma: In other cell systems, ABT-737 was also shown to have synergistic action with other agents like cytotoxic drugs in inducing cell death like carboplatin against ovarian cancer and SCLC [37, 68], etoposide against SCLC [38], docetaxel against breast cancer [69] as well as kinase inhibitors like PI3 kinase and mTOR inhibitors in SCLC and colorectal cancer cells [70, 71].